European Journal of Clinical Pharmacology (2018) 74:1361–1362 https://doi.org/10.1007/s00228-018-2492-7 LETTER TO THE EDITOR The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease 1 2 3 4 1,4 4 David Pineles & Lisa Malter & Peter S. Liang & Amy Arsuaga & Brian Bosworth & David P. Hudesman & Shannon Chang Received: 29 April 2018 / Accepted: 22 May 2018 / Published online: 31 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 We read with great interest a recent paper by Boone et al. . penetration into our marketplace has only recently accelerated. In this 1-year observational study, the authors sought to quan- As such, we recently performed a small, prospective study tify the nocebo rate in individuals with an immune-mediated aimed at gauging IBD patients’ initial perceptions of inflammatory disease who were switched from the originator biosimilars. In 2017, we surveyed 132 adult patients with infliximab to a biosimilar for a non-medical reason. Patients IBD at two university-affiliated gastroenterology clinics regard- were provided informed consent and voluntarily agreed to ing their current impression of biosimilars. A standardized cov- transition to the infliximab biosimilar. The patients in this er sheet was included with the 14-question survey
European Journal of Clinical Pharmacology – Springer Journals
Published: May 31, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud